{"prompt": "['Novartis', 'Confidential', 'Page 18', 'Amended Protocol Version v02/Clean', 'Protocol No. CQVM149B2306', '3', 'Investigational plan', '3.1 Study design', 'This study uses a multicenter, partially-blinded, randomized, 24-week, parallel-group, non-', 'inferiority, open-label active controlled design.']['Novartis', 'Confidential', 'Page 19', 'Amended Protocol Version v02/Clean', 'Protocol No. CQVM149B2306', 'The study will consist of a screening period of up to 1-week, run-in period of 2-weeks,', 'randomized treatment period of 24-weeks, and a follow-up of period of 1-week.', 'At Visit 1, informed consent will be obtained before any study related assessments or', 'procedures are performed. All patients signing informed consent must be registered in the', 'Interactive Response Technology (IRT). Asthma medications and eligibility criteria will be', 'reviewed. All patients must have used inhaled LABA+ ICS for at least 3 months and been on', 'stable medium or high dose LABA+ ICS for at least 1 month prior to Visit 1. If necessary,', 'arrangements will be made to adjust concurrent and prohibited medications (Table 5-2, Table', '5-3, and Table 5-4) before moving forward to Visit 101. Once concurrent medications', 'comply with the requirements of the study patients will conduct Visit 101. Visit 1 and Visit', '101 may be performed on the same day if concurrent medications comply with the', 'requirements of the study (LABA + ICS must not be used within 12 hours for twice daily and', '24 hours for once daily before Visit 101). Visit 1 and Visit 101 should be conducted as close', 'together as possible based on adjustments of prohibited medications.', 'All patients that meet eligibility criteria at Visit 1 will be provided a short-acting \u00df-2 agonist', '(salbutamol) for use as a rescue inhaler on an \"as needed\" basis throughout the study; for', 'more details on rescue medication please refer to Section 5.5.6.', 'At Visit 101 all additional screening assessments, including a reversibility test to assess', \"eligibility (see Appendix 2 Spirometry), and an ECG to evaluate patients' cardiovascular\", 'safety, must be conducted. Patients who qualify will enter a 2-week run-in period.', 'Patients will be supplied with open-label LABA/ICS salmeterol /fluticasone 50/250 g b.i.d.', 'or 50/500 g b.i.d, to match their background medication, which will be used throughout the', 'Run-in and stopped at Visit 201. Patients will also be supplied with an electronic diary', '(eDiary) combined with Peak Flow meter to record asthma symptoms, rescue medication use,', 'and PEF.', 'Upon completion of the run-in period at Visit 201 patients will return to the clinic. All', 'patients who meet the eligibility criteria will be randomized in a 1:1:1 ratio to one of the three', 'treatment arms (Section 5.2). Patients will be stratified at Visit 201 randomization according', 'to the ICS dose component of background ICS/LABA (medium or high dose) and region.', 'The first dose of study medication will be administered at the clinic in the evening (between', '5:00 and 8:00 pm) at Visit 201 (Day 1). Randomized patients will enter the 24 week treatment', 'period during which visits must be scheduled to allow randomized study treatment to be taken', 'in the evening at the clinic. Patients must be instructed not to take their evening dose of study', 'medication prior to all future clinic visits, as these doses will be administered in clinic after all', 'pre-dose assessments have been performed. All treatment period visits should be conducted', 'at approximately the same time throughout the study to ensure pre-dose spirometry is', 'performed and study treatment is taken at approximately the same time.', 'All randomized patients will be contacted (by telephone) 7 days following the last dose of', 'study medication or last visit, whichever is later, for Visit 301 (Safety Follow-up).']['Novartis', 'Confidential', 'Page 20', 'Amended Protocol Version v02/Clean', 'Protocol No. CQVM149B2306', 'Figure 3-1', 'Study design', 'Screening', 'Run-in', 'Randomized Treatment', 'Follow-up', '(7 days)', 'I', 'I', 'I', 'I', 'I', 'I', 'I', 'QVM149 150/50/80 g o.d. via Concept1', 'I', 'Open label', 'I', 'Salmeterol /', 'I', 'I', 'Fluticasone', 'I', 'I', '50/250 ng b.i.d.', 'QVM149 150/50/160 g o.d. via Concept1', 'or 50/500 g', '1', 'b.i.d', 'I', 'Open label Salmeterol /Fluticasone 50/500 g b.i.d. via Diskus', '+ Tiotropium 5 g o.d via Respimat\u00ae', 'Day -21', 'Day 14', 'to', 'to', 'Day-14', 'Day 1', 'Day 1 to Day 169', 'Visit 1', 'Visit 101', 'Visit 201', 'Visit 204', 'Visit 301', 'Randomization', '3.2 Rationale for study design', 'A multicenter, partially-blinded, randomized, 24-week, parallel-group, non-inferiority, open-', 'label active controlled study in patients with uncontrolled asthma on medium to high dose', 'ICS/LABA was chosen to evaluate the efficacy and safety of 2 strengths of the fixed triple', 'combination treatment QVM149 VS the free triple combination treatment salmeterol/', 'fluticasone + tiotropium. The general design is well-established in respiratory clinical trials', 'and enables the study treatments to be given for an appropriate and practical length of time to', 'assess the efficacy and safety of the treatments. The study has an open-label component (free', 'triple combination of salmeterol/fluticasone + tiotropium for which investigators and patients', 'will have full knowledge of treatment allocation. However, in order to minimize the potential', 'impact, measures will be taken to blind the sponsor team from knowledge of treatment', 'allocation. In addition, within the two QVM149 treatment arms all parties including patients', 'and investigators will remain blinded to the actual dose. The identity of the QVM149', 'strengths will be concealed by the use of study drugs that are all identical in packaging,', 'labeling, schedule of administration, appearance, taste and odor.', 'The open-label design of the study will reduce the burden of a triple dummy treatment', 'regimen for participating patients.', 'An improvement of 0.5 points in AQLQ score is considered to be the minimally clinically', 'important difference (MCID) in asthma. A non-inferiority margin of 0.25 points reduction in', 'AQLQ score has been designated for the study based upon 50% of the MCID. If the MCID of', '0.5 points reduction in the AQLQ is considered clinically important, it is reasonable to use a', 'non-inferiority margin of one-half of this difference, which is 0.25 points.']\n\n###\n\n", "completion": "END"}